|
|
|
| The Market Overview of Monoclonal Antibodies in Both Domestic and Abroad |
| LI Min1, WU Ri-wei2 |
1. Institute of Science and Technology Strategy, Jiangxi Academy of Sciences, Nanchang 330096, China;
2. Nanchang National High-Tech Industrial Development, Nanchang 330096, China |
|
|
|
Abstract With the advantages of good targeting ability and less adverse reactions, monoclonal antibodies industry has grown rapidly in various therapeutic areas including tumor and autoimmune diseases. There are 55 kinds of antibody drugs in global market and the global sales have reached 91.63 billion dollar in 2015. Currently, China is in the stage of rapid development of antibody drugs. At present, 22 kinds of monoclonal antibodies were approved by CFDA, containing 10 kinds of domestic products and 12 kinds of imported products. The market scale of domestic monoclonal antibodies is 5.034 billion yuan in 2014. With the development of biotechnology, the market prospects of domestic monoclonal antibodies will become more and more extensive.
|
|
Received: 26 July 2016
Published: 25 March 2017
|
|
|
|
|
| [1] 甄永苏. 抗体药物与肿瘤靶向治疗. 医学研究杂志, 2007, 36(2):1-2. Zhen Y S. Antibody drugs and tumor targeted therapy. Journal of Medical Research, 2007, 36(2):1-2.
[2] 张弢, 陈卫, 浦迪, 等. 抗体药物研究进展与趋势. 中国新药杂志, 2008, 17(9):713-718. Zhang T, Chen W, Pu D, et al. The develpoment and trend of antibody drug. Chinese Journal of New Drug, 2008, 17(9):713-718.
[3] 刘萍, 陈苗苗, 刘学荣,等. 单克隆抗体研究进展. 中国畜牧兽医, 2012, 39(1):67-70. Liu P, Chen M M, Liu X R, et al. Research progress in monoclonal antibodies. China Animal Husbandry & Veterinary Medicine, 2012, 39(1):67-70.
[4] 姚瑞. 单克隆抗体行业研究.成都:西南财经大学, 金融学院, 2014. Yao R. The Monoclonal Antibody Industry Analysis. Chengdu:Southwestern University of Finance and Economics, School of Finance, 2014.
[5] 李壮林, 姚雪静. 单克隆抗体药物研究进展. 药物生物技术, 2014, 21(05):456-461. Li Z L, Yao X J. Research and development of monoclonal antibody drugs. Pharmaceutical Biotechnology, 2014, 21(05):456-461.
[6] Beck A, Wurch T, Reichert T J M. 6th annual report antibody congress 2010. Mabs, 2011, 3(2):111-132.
[7] Weiner L M, Surana R, Wang S. Monoclonal antibodies:versatile platforms for cancer immunotherapy. Nat Rev Immunol, 2010,10(5):317-327.
[8] Chan A C, Carter P J. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol, 2010, 10(5):301-316.
[9] 李心, 龚珉, 徐为人, 等. 抗体药物的国内外市场动态. 现代药物与临床, 2012, 27(3):185-191. Li X, Gong M, Xu W R, et al. Market dynamics of antibody drugs in both domestic and abroad. Drugs & Clinic, 2012, 27(3):185-191.
[10] 马杉姗, 马素永, 赵广荣. 中国抗体药物产业现状与发展前景. 中国生物工程杂志, 2015, 35(12):103-108. Ma S S, Ma S Y, Zhao G R. The status and development prospect of Chinese antibody drug industry. China Biotechnology, 2015, 35(12):103-108.
[11] . Gao K, Wang J Z. The biopharmaceutical industry in China:history and future perspectives. Front Med, 2012, 6(2):101-111.
[12] 王兰,朱磊,徐刚领, 等. 单克隆抗体类生物治疗药物研究进展. 中国药学杂志, 2014, 49(23):2058-2064. Wang L, Zhu L, Xu G L, et al. Progress of research and development of antibody-based therapeutics. Chinese Pharmaceutical Journal, 2014, 49(23):2058-2064. |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
